• Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.
  • While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.
  • Diagnosing dementia currently takes 3.5 years on average,11 and an estimated 75% of people living with dementia remain undiagnosed. Elecsys® pTau217 offers a simple blood test to aid in earlier, more accessible Alzheimer's disease diagnosis for millions of patients around the world.